Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.
Alexeeva E, Krekhova E, Dvoryakovskaya T, Isaeva K, Chomakhidze A, Chistyakova E, Lomakina O, Denisova R, Mamutova A, Fetisova A, Gautier M, Vankova D, Kriulin I, Saygitov R. Alexeeva E, et al. Among authors: fetisova a. Front Pediatr. 2023 Feb 22;11:1114207. doi: 10.3389/fped.2023.1114207. eCollection 2023. Front Pediatr. 2023. PMID: 36911042 Free PMC article.
Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI, Namazova-Baranova LS, Bzarova TM, Valieva SI, Denisova RV, Sleptsova TV, Isaeva KB, Chomahidze AM, Taibulatov NI, Fetisova AN, Karaseva AV, Baranov AA. Alexeeva EI, et al. Among authors: fetisova an. Pediatr Rheumatol Online J. 2017 Jun 14;15(1):51. doi: 10.1186/s12969-017-0178-9. Pediatr Rheumatol Online J. 2017. PMID: 28615036 Free PMC article.
Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method.
Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, Fetisova A, Mamutova A, Alshevskaya A, Gladkikh V, Moskalev A. Alexeeva E, et al. Among authors: fetisova a. Mod Rheumatol. 2019 Sep;29(5):848-855. doi: 10.1080/14397595.2018.1516329. Epub 2019 Jan 3. Mod Rheumatol. 2019. PMID: 30149747
Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.
Alexeeva E, Shingarova M, Dvoryakovskaya T, Lomakina O, Fetisova A, Isaeva K, Chomakhidze A, Chibisova K, Krekhova E, Kozodaeva A, Savostyanov K, Pushkov A, Zhanin I, Demyanov D, Suspitsin E, Belozerov K, Kostik M. Alexeeva E, et al. Among authors: fetisova a. Front Med (Lausanne). 2023 Nov 15;10:1257045. doi: 10.3389/fmed.2023.1257045. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38034538 Free PMC article.
RNAseq profiling of blood from patients with coronary artery disease: Signature of a T cell imbalance.
McCaffrey TA, Toma I, Yang Z, Katz R, Reiner J, Mazhari R, Shah P, Falk Z, Wargowsky R, Goldman J, Jones D, Shtokalo D, Antonets D, Jepson T, Fetisova A, Jaatinen K, Ree N, Ri M. McCaffrey TA, et al. Among authors: fetisova a. J Mol Cell Cardiol Plus. 2023 Jun;4:100033. doi: 10.1016/j.jmccpl.2023.100033. Epub 2023 Mar 25. J Mol Cell Cardiol Plus. 2023. PMID: 37303712 Free PMC article.
Crossbar Nanoscale HfO2-Based Electronic Synapses.
Matveyev Y, Kirtaev R, Fetisova A, Zakharchenko S, Negrov D, Zenkevich A. Matveyev Y, et al. Among authors: fetisova a. Nanoscale Res Lett. 2016 Dec;11(1):147. doi: 10.1186/s11671-016-1360-6. Epub 2016 Mar 15. Nanoscale Res Lett. 2016. PMID: 26979725 Free PMC article.
20 results